Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Design and methods for the Ranger Resilience and Improved Performance on Phospholipid bound Omega-3's (RRIPP-3 study).

Marriott BP, Turner TH, Hibbeln JR, Pregulman M, Newman J, Johnson KB, Malek AM, Malcolm RJ, Burbelo GA, Wissman JW; RRIPP-3 Group.

Contemp Clin Trials Commun. 2019 Apr 26;15:100359. doi: 10.1016/j.conctc.2019.100359. eCollection 2019 Sep.

2.

Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review.

Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE.

Front Psychiatry. 2018 Jul 24;9:277. doi: 10.3389/fpsyt.2018.00277. eCollection 2018. Review.

3.

Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users.

Sahlem GL, Baker NL, George MS, Malcolm RJ, McRae-Clark AL.

Am J Drug Alcohol Abuse. 2018;44(1):47-55. doi: 10.1080/00952990.2017.1355920. Epub 2017 Aug 14.

4.

Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.

Zhu HJ, Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Shi J, Johnson HJ, Knight JM, Smith AT, Malcolm RJ, Markowitz JS.

J Clin Psychopharmacol. 2017 Aug;37(4):419-428. doi: 10.1097/JCP.0000000000000721.

5.

Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial.

Holland-Carter L, Tuerk PW, Wadden TA, Fujioka KN, Becker LE, Miller-Kovach K, Hollander PL, Garvey WT, Weiss D, Rubino DM, Kushner RF, Malcolm RJ, Raum WJ, Hermayer KL, Veliko JL, Rost SL, Sora ND, Salyer JL, O'Neil PM.

J Diabetes Complications. 2017 May;31(5):891-897. doi: 10.1016/j.jdiacomp.2017.01.022. Epub 2017 Feb 16.

6.

Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, Walsh SL.

Drug Alcohol Depend. 2017 Mar 1;172:9-13. doi: 10.1016/j.drugalcdep.2016.11.030. Epub 2016 Dec 14.

7.

Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes.

O'Neil PM, Miller-Kovach K, Tuerk PW, Becker LE, Wadden TA, Fujioka K, Hollander PL, Kushner RF, Timothy Garvey W, Rubino DM, Malcolm RJ, Weiss D, Raum WJ, Salyer JL, Hermayer KL, Rost SL, Veliko JL, Sora ND.

Obesity (Silver Spring). 2016 Nov;24(11):2269-2277. doi: 10.1002/oby.21616.

8.

Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.

Mariani JJ, Malcolm RJ, Mamczur AK, Choi JC, Brady R, Nunes E, Levin FR.

Am J Drug Alcohol Abuse. 2016 May;42(3):333-40. doi: 10.3109/00952990.2015.1125493. Epub 2016 Mar 10.

9.

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL.

Neuropsychopharmacology. 2016 Jul;41(8):1974-82. doi: 10.1038/npp.2015.367. Epub 2015 Dec 28.

10.

Dietary adherence and satisfaction with a bean-based high-fiber weight loss diet: a pilot study.

Turner TF, Nance LM, Strickland WD, Malcolm RJ, Pechon S, O'Neil PM.

ISRN Obes. 2013 Oct 29;2013:915415. doi: 10.1155/2013/915415. eCollection 2013.

11.

Potential role of N-acetylcysteine in the management of substance use disorders.

McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM.

CNS Drugs. 2014 Feb;28(2):95-106. doi: 10.1007/s40263-014-0142-x. Review.

12.

Changes in cardiovascular risk factors with participation in a 12-week weight loss trial using a commercial format.

Milsom VA, Malcolm RJ, Johnson GC, Pechon SM, Gray KM, Miller-Kovach K, Rost SL, O'Neil PM.

Eat Behav. 2014 Jan;15(1):68-71. doi: 10.1016/j.eatbeh.2013.10.004. Epub 2013 Oct 21.

PMID:
24411753
13.

Low frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex transiently increases cue-induced craving for methamphetamine: a preliminary study.

Li X, Malcolm RJ, Huebner K, Hanlon CA, Taylor JJ, Brady KT, George MS, See RE.

Drug Alcohol Depend. 2013 Dec 1;133(2):641-6. doi: 10.1016/j.drugalcdep.2013.08.012. Epub 2013 Aug 26.

14.

A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence.

LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ.

Am J Addict. 2013 Sep-Oct;22(5):443-52. doi: 10.1111/j.1521-0391.2013.12034.x. Epub 2013 May 15.

15.

Effects of intravenous nicotine on prepulse inhibition in smokers and non-smokers: relationship with familial smoking.

Drobes DJ, MacQueen DA, Blank MD, Saladin ME, Malcolm RJ.

Psychopharmacology (Berl). 2013 Sep;229(2):285-94. doi: 10.1007/s00213-013-3107-8. Epub 2013 Apr 28.

16.

Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans.

Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Bell GH, Anderson ER, Malcolm RJ.

Drug Metab Dispos. 2013 Jan;41(1):197-205. doi: 10.1124/dmd.112.048595. Epub 2012 Oct 25.

17.
18.

The Obsessive Compulsive Cocaine Scale: assessment of factor structure, reliability, and validity.

Jardin BF, Larowe SD, Hall BJ, Malcolm RJ.

Addict Behav. 2011 Dec;36(12):1223-7. doi: 10.1016/j.addbeh.2011.07.028. Epub 2011 Jul 29.

19.

Glutamatergic medications for the treatment of drug and behavioral addictions.

Olive MF, Cleva RM, Kalivas PW, Malcolm RJ.

Pharmacol Biochem Behav. 2012 Feb;100(4):801-10. doi: 10.1016/j.pbb.2011.04.015. Epub 2011 Apr 22. Review.

20.

Distinctive characteristics of methamphetamine users presenting at public clinics: steep rise in South Carolina, United States, 2000-2005.

Korte JE, Hiott FB, Brady KT, Malcolm RJ, See RE.

Drug Alcohol Depend. 2011 May 1;115(1-2):9-15. doi: 10.1016/j.drugalcdep.2010.09.023. Epub 2010 Dec 9.

Supplemental Content

Loading ...
Support Center